English Polski

Wyszuk. zaawans.

  • Folia Cardiologica
  • Tom 10, Nr 1 (2015) Nowe kierunki badań nad doustnymi antykoagulantami niebędącymi antagonistami witaminy K u progu 2015 roku — na wyniki jakich badań klinicznych czekamy?
Tom 10, Nr 1 (2015)
Artykuł przeglądowy
Opublikowany online: 2015-03-02

dostęp otwarty

Pokaż PDF Pobierz plik PDF
Wyświetlenia strony 1096
Wyświetlenia/pobrania artykułu 5413
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Nowe kierunki badań nad doustnymi antykoagulantami niebędącymi antagonistami witaminy K u progu 2015 roku — na wyniki jakich badań klinicznych czekamy?

Mariusz Tomaniak, Aleksandra Gąsecka, Krzysztof J. Filipiak
DOI: 10.5603/FC.2015.0006
Folia Cardiologica 2015;10(1):25-37.

Streszczenie

Doustne antykoagulanty niebędące antagonistami witaminy K (NOAC) nie są już tematem nowym. Wyniki metaanaliz podsumowujących badania kliniczne nad bezpieczeństwem i skutecznością NOAC wskazują, że leki te stanowią bardzo obiecującą grupę terapeutyczną, dlatego ich zastosowanie w codziennej praktyce klinicznej będzie odgrywało coraz większą rolę. Trwające wieloośrodkowe badania prawdopodobnie pozwolą na dalsze rozszerzenie wskazań klinicznych do stosowania NOAC, a także pomogą rozwiązać problemy kliniczne stojące obecnie na przeszkodzie w ich upowszechnieniu. W niniejszym artykule podsumowano najważniejsze kierunki prowadzonych obecnie badań z zastosowaniem NOAC.

Słowa kluczowe: doustne antykoagulanty niebędące antagonistami witaminy KNOACmigotanie przedsionkówpowikłania zakrzepowo-zatorowefarmakoterapia

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Stępińska J, Wożakowaka-Kapłon B, Pruszczyk P, et al. Doustne antykoagulanty non-VK już nie „nowe”! Kardiologia Polska. 2014; 72(9): 854–855.
    CrossRef
  2. Mitchell SA, Simon TA, Raza S, et al. The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis. Clin Appl Thromb Hemost. 2013; 19(6): 619–631.
    CrossRefPubMed
  3. Kakkos SK, Kirkilesis GI, Tsolakis IA. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg. 2014; 48(5): 565–575.
    CrossRefPubMed
  4. Friedman RJ. Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials. Orthopedics. 2011; 34(10): 795–804.
    CrossRefPubMed
  5. Stevenson M, Scope A, Holmes M, et al. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Health Technol Assess. 2009; 13 Suppl 3: 43–48.
    CrossRefPubMed
  6. Deeks ED. Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery. Drugs. 2012; 72(9): 1271–1291.
    CrossRefPubMed
  7. Guyatt GH, Akl EA, Crowther M, et al. American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): 7S–747S.
    CrossRefPubMed
  8. Hijazi Z, Oldgren J, Lindbäck J, et al. ARISTOTLE and RE-LY Investigators, RE-LY Investigators, RE-LY study group, RE-LY investigators, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139–1151.
    CrossRefPubMed
  9. Sun Y, Hu D, Stevens S, et al. ROCKET AF Steering Committee and Investigators, ROCKET AF Investigators, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–891.
    CrossRefPubMed
  10. Granger CB, Alexander JH, McMurray JJV, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981–992.
    CrossRefPubMed
  11. Link MS, Giugliano RP, Ruff CT, et al. ENGAGE AF-TIMI 48 Investigators, ENGAGE AF-TIMI 48 Investigators, ENGAGE AF-TIMI 48 Investigators, ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22): 2093–2104.
    CrossRefPubMed
  12. Camm AJ, Lip GYH, De Caterina R, et al. ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012; 33(21): 2719–2747.
    CrossRefPubMed
  13. Schulman S, Kearon C, Kakkar AK, et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 363: 2499–2510.
    CrossRefPubMed
  14. Bauersachs R, Berkowitz SD, Brenner B, et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26): 2499–2510.
    CrossRefPubMed
  15. Büller HR, Prins MH, Lensin AWA, et al. EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366(14): 1287–1297.
    CrossRefPubMed
  16. Agnelli G, Buller HR, Cohen A, et al. AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369(9): 799–808.
    CrossRefPubMed
  17. Büller HR, Décousus H, Grosso MA, et al. Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369(15): 1406–1415.
    CrossRefPubMed
  18. Konstantinides SV, Torbicki A, Agnelli G, et al. Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014; 35(43): 3033-3069–3069a-1069k.
    CrossRefPubMed
  19. Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013; 34(27): 2094–2106.
    CrossRefPubMed
  20. Sardar P, Chatterjee S, Herzog E, et al. Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. Can J Cardiol. 2014; 30(8): 888–897.
    CrossRefPubMed
  21. Sardar P, Chatterjee S, Chaudhari S, et al. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc. 2014; 62(5): 857–864.
    CrossRefPubMed
  22. Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest. 2013; 144(5): 1555–1563.
    CrossRefPubMed
  23. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 2014; 35: 2603–2605.
  24. Law EH, Gordon W. Target-specific oral anticoagulants in patients undergoing cardioversion. Am J Health Syst Pharm. 2014; 71(14): 1171–1176.
    CrossRefPubMed
  25. Cappato R, Ezekowitz MD, Klein AL, et al. X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014; 35(47): 3346–3355.
    CrossRefPubMed
  26. John H. Stroger Hospital. Anticoagulation with rivaroxaban in cardioversion — the ARC study. NLM Identifier: NCT01747746. http://clinicaltrials.gov/ct2/show/NCT01747746 (2012).
  27. Musat D, Garikipati N, Taub J, et al. Novel oral anticoagulants vs continuous warfarin peri-ablation of atrial fibrillation: a meta-analysis of embolic and bleeding complications. Eur. Heart J. 2014; 35(supl.): 390.
  28. German Atrial Fibrillation Network. Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy (AXAFA). NLM Identifier: NCT02227550. https://clinicaltrials. gov/ct2/show/NCT02227550 (2014).
  29. Ottawa Heart Institute Research Corporation. Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial (OCEAN). NLM Identifier: NCT02168829. https:////clinicaltrials.gov/ct2/show/NCT02168829 (2014).
  30. Calkins H, Kuck KH, Cappato R, et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2012; 9: 632–696.
  31. Japan Cardiovascular Research Foundation. RELAXED: recurrent embolism lessened by rivaroxaban for acute ischemic stroke. NLM Identifier: NCT02129920. http://clinicaltrials.gov/ct2/ /show/NCT02129920 (2014).
  32. Asan Medical Center. Rivaroxaban versus warfarin in acute ischemic stroke with atrial fibrillation(TripleAXEL). NLM Identifier: NCT02042534. http://clinicaltrials.gov/ct2/show/ /NCT02042534 (2014).
  33. Boehringer Ingelheim. Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS). NLM Identifier: NCT02239120. https://clinicaltrials.gov/ct2/show/NCT02239120 (2014).
  34. Bayer. Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (NAVIGATE ESUS). NLM Identifier: NCT02313909. https://clinicaltrials.gov/ct2/show/ /NCT02313909 (2014).
  35. Healey JS, Connolly SJ, Gold MR, et al. ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012; 366(2): 120–129.
    CrossRefPubMed
  36. Population Health Research Institute. Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA). NLM Identifier: NCT01938248. . https://clinicaltrials.gov/ct2/show/NCT01938248 (2014).
  37. Birnie DH, Healey JS, Wells GA, et al. BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013; 368(22): 2084–2093.
    CrossRefPubMed
  38. Ottawa Heart Institute Research Corporation. Strategy of Continued Versus Interrupted Dabigatran at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events (BRUISE CONTROL 2). NLM Identifier: NCT01675076. . https://clinicaltrials.gov/ct2/show/study/NCT01675076 (2013).
  39. Bayer. Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS). NLM Identifier: NCT01776424. https://www.clinicaltrials.gov/ct2/ /show/NCT01776424 (2013).
  40. Janssen Research & Development, LLC. A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure (COMMANDER HF). NLM Identifier: NCT01877915. https://clinicaltrials.gov/ct2/show//record/NCT01877915 (2013).
  41. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383(9921): 955–962.
    CrossRefPubMed
  42. FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfari. http://www.fda.gov/Drugs/DrugSafety//ucm396470 (13.05.2014).
  43. Mima Y, Sangatsuda Y, Yasaka M, et al. Acute thrombocytopenia after initiating anticoagulation with rivaroxaban. Intern Med. 2014; 53(21): 2523–2527.
    PubMed
  44. Glund D., Stangier J., Schmohl M. i wsp. Abstract: Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects. 56th ASH Annual Meeting & Exposition San Francisco, 06-09.12.2014.
  45. Boehringer Ingelheim Press Release — 30 czerwca 2014. U.S. FDA grants Breakthrough Therapy Designation to dabigatran etexilate specific investigational antidote. . http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/30_ _june_2014_dabigatranetexilate.html (30.06.2014).
  46. Boehringer Ingelheim. A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran (REVERSE AD). NLM Identifier: NCT02104947. https://clinicaltrials.gov/ct2/show/ /NCT02104947 (4947).
  47. Portola Pharmaceuticals News Release — 9 stycznia 2015, San Francisco. Phase 3 ANNEXA-R Study of Andexanet Alfa and Factor Xa Inhibitor XARELTO(R) (rivaroxaban) Met Primary Endpoint With High Statistical Significance. . http://investors.portola.com//phoenix.zhtml?c=198136&p=irol-newsArticle&ID=2005429 (09.01.2015).
  48. Portola Pharmaceuticals. A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban. NLM Identifier: NCT02220725. https://clinicaltrials.gov/ct2/show/NCT02220725 (2014).
  49. Portola Pharmaceuticals. A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban. NLM Identifier: NCT02207725. https://clinicaltrials.gov/ct2/show/NCT02207725 (2014).
  50. Connolly SJ, Wallentin L, Ezekowitz MD, et al. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation. 2013; 128(3): 237–243.
    CrossRefPubMed
  51. Labaf A, Carlwe M, Svensson PJ. Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden. Thromb J. 2014; 12(1): 29.
    CrossRefPubMed
  52. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013; 368(14): 1272–1274.
    CrossRefPubMed
  53. Boehringer Ingelheim. GLORIA-AF Registry Program — Second and Third Phases. NLM Identifier: NCT01468701. https://clinicaltrials.gov/ct2/show/NCT01468701 (2011).
  54. anssen Scientific Affairs, LLC. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). NLM Identifier: NCT01701817. https://clinicaltrials.gov/ct2/show/ /NCT01701817 (2013).
  55. Lippi G, Favaloro EJ. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? Clin Chem Lab Med. 2015; 53(2): 185–197.
    CrossRefPubMed
  56. Cuker A, Siegal DM, Crowther MA, et al. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014; 64(11): 1128–1139.
    CrossRefPubMed

Informacje o plikach cookie

Niezbędne pliki cookie

Zawsze aktywne

Te pliki cookie są niezbędne do prawidłowego wyświetlania i działania strony internetowej. Zablokowanie ich może spowodować nieprawidłowe działanie strony.

Analityczne pliki cookie

W ramach naszej strony internetowej korzystamy z narzędzi analitycznych, takich jak Google Analytics, które umożliwiają nam weryfikację ruchu na stronie internetowej. Narzędzia te mogą wymagać użycia plików cookie.

Społecznościowe pliki cookie

Są to pliki cookie powiązane z portalami społecznościowymi, z których korzystamy. Zaakceptowanie ich pozwoli na powiązanie Twojej wizyty na stronie z naszymi profilami w mediach społecznościowych.

Marketingowe pliki cookie

Są to pliki cookie odpowiedzialne za prowadzenie działań reklamowych i marketingowych - zgoda na ich wykorzystanie pozwoli nam kierować do Ciebie reklamy, bazujące na podstawie Twoich wcześniejszych aktywności w ramach naszej stronie internetowej.

Copyright © 2023-2024 Via Medica Regulamin Polityka cookies Polityka prywatności Nota prawna